News & Updates

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Targeting interleukin-31 signalling with nemolizumab appears to produce substantial improvements in core signs and symptoms of prurigo nodularis (PN), as shown in the phase III OLYMPIA 1 trial.

New research shows limited transmission of the rotavirus vaccine strains in neonatal intensive care units (NICUs), suggesting that the benefits of vaccination outweigh earlier concerns.

Treatment with tirzepatide reduced the risk of cardiovascular (CV) death and worsening heart failure (HF) in patients with HF with preserved ejection fraction (HFpEF) and obesity, according to the SUMMIT trial presented at AHA 2024.

In the treatment of patients with hypertension, the use of chlorthalidone does not appear to yield superior kidney outcomes when compared with hydrochlorothiazide but is associated with an increased risk of hypokalemia, as reported in a study.

For people with long-term stable multiple sclerosis (MS) who use disease-modifying therapy (DMT) in the first-line setting, discontinuation spells an increased hazard of inflammatory disease activity recurrence, as shown in a study.

In the treatment of women with early pregnancy loss, adding mifepristone to misoprostol helps reduce the incidence of treatment failure as compared with misoprostol alone, according to a retrospective study.

Healthcare workers who developed depression in the course of frontline work during the COVID-19 pandemic experienced substantial reductions in symptoms following psilocybin treatment, as shown in a small randomized clinical trial.